中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Issue 4
Apr.  2016

Effect of “treating liver by nourishing spleen”on gut microbiota in rats with liver fibrosis based on Xiaoyao powder and its separated recipe

DOI: 10.3969/j.issn.1001-5256.2016.04.009
Research funding:

 

  • Published Date: 2016-04-20
  • Objective To investigate the possible mechanism of“treating liver by nourishing spleen”in the treatment of liver fibrosis with reference to the effect of Xiaoyao powder and its separated recipe on gut microbiota and the level of portal endotoxins. Methods A total of70 healthy Wistar rats were randomly divided into blank group( 10 rats),model group( 20 rats),experimental group( 20 rats),and control group( 20 rats),and tail vein injection of bovine serum albumin was performed for 8 weeks to establish a rat model of immune liver fibrosis.The rats in the experimental group were given Xiaoyao granules by gavage,and those in the control group were given Xiaoyao granules without the spleen- strengthening traditional Chinese medicines Atractylodes macrocephala Koidz.,Poria cocos,ginger,and Radix Glycyrrhizae Preparata by gavage. Serum aminotransferases,liver pathology,portal endotoxins,and the enterobacterial repetitive intergenic consensus( ERIC)- PCR fingerprint of gut microbiota were observed in each group. The analysis of variance was applied for comparison of continuous data with homogeneity of variance between multiple groups,and the least significant difference t- test was used for further comparison between any two groups; the Tamhane's method was applied for data with heterogeneity of variance; the Pearson correlation analysis was used for correlation analysis. Results Compared with the blank group,the model group showed changes in the diversity and structure of gut microbiota and an increase in the level of portal endotoxins( 0. 421 ± 0. 170 EU / ml vs 0. 784 ± 0. 180 EU / ml),which showed significant differences between these two groups( P < 0. 01),and the level of portal endotoxins was positively correlated with collagen area percentage in liver tissue( r = 0. 736,P < 0. 01). Compared with the model group,the experimental group had significantly reduced levels of alanine aminotransferase( ALT),aspartate aminotransferase( AST),and portal endotoxins( 73. 25 ± 10. 90 U / L vs 59. 84 ± 9. 60 U / L,135. 36 ±31. 41 U / L vs 107. 43 ± 17. 71 U / L,0. 784 ± 0. 180 EU / ml vs 0. 576 ± 0. 220 EU / ml,P < 0. 01 or P < 0. 05),and the rats in the experimental group had similar diversity and structure of gut microbiota as normal rats. The levels of ALT,AST,and portal endotoxins showed no significant differences between the experimental group and the control group( P > 0. 05). Conclusion The rats with liver fibrosis experience intestinal dysbacteriosis which causes the increase in portal endotoxins,and it is one of the mechanisms for the pathogenesis of “liver disease affecting spleen”during the pathological process of chronic liver injury. Xiaoyao powder can relieve liver fibrosis,partially restore the normal structure of gut microbiota,and reduce endotoxins,while the removal of the spleen- strengthening drugs will weaken the protective effect of Xiaoyao powder on the liver. This suggests that restoration of gut microbiota and reduction of portal endotoxins may be an important mechanism of “treating liver by nourishing spleen”in the treatment of liver fibrosis.

     

  • [1]SEO YS,SHAH VH.The role of gut-liver axis in the pathogenesis of liver cirrhosis and portal hypertension[J].Clin Mol Hepatol,2012,18(4):337-346.
    [2]ZHU WF,SUN KW,CHEN B,et al.Analysis of the intestinal flora of hepatitis B-related liver failure with different jaundice syndrome[J].J Hunan Univ TCM,2013,33(1):128-131.(in Chinese)朱文芳,孙克伟,陈斌,等.乙型肝炎相关性肝衰竭不同黄疸证的肠道菌群分析[J].湖南中医药大学学报,2013,33(1):128-131.
    [3]CHEN B,SUN KW,LIU MD,et al.An experimental study on the effect of zedoary on the membrane function of hepatocytes among rats with immune-injuring induced hepatic fibrosisi[J].J Hunan Univ TCM,2003,23(1):7-8.(in Chinese)陈斌,孙克伟,刘明德,等.莪术对免疫性肝纤维化大鼠肝细胞膜功能的影响[J].湖南中医学院学报,2003,23(1):7-8.
    [4]ISHAK K,BAPTISTA A,BIANCHI L,et al.Histological grading and staging of chronic hepatitis[J].J Hepatol,1995,22(6):696-699.
    [5]ZHOU W,CHEN B,PENG J,et al.Effect of Wengyang jiedu huayu granule on tight connection of colon mucosain rats with intestinal endotoxemia[J].Chin J Integr Tradit West Med Liver Dis,2014,24(3):156-158.(in Chinese)周为,陈斌,彭杰,等.温阳解毒化瘀颗粒对肠源性内毒素血症大鼠肠黏膜上皮紧密连接的影响[J].中西医结合肝病杂志,2014,24(3):156-158.
    [6]LIU J,PENG Y,ZHANG SY,et al.Investigation on intestinal microflora of elderly patients with spleen deficiency by 16S rD NADGGE analysis[J].Chin Arch Tradit Chin Med,2010,25(10):1566-1569.(in Chinese)刘佳,彭颖,张硕颖,等.老年脾虚患者肠道菌群16S rD NA变性梯度凝胶电泳分析[J].中华中医药杂志,2010,25(10):1566-1569.
    [7]WANG Z,PENG Y,LI XB.Effect of sijunzi decoction on the intestinal flora disturbance in two rat models of PI-deficiency syndrome[J].Chin J Integr Tradit West Med(Chin),2009,29(9):825-829.(in Chinese)王卓,彭颖,李晓波.四君子汤对两种脾虚模型大鼠肠道菌群紊乱的影响[J].中国中西医结合杂志,2009,29(9):825-829.
    [8]WENG QQ.A comparative study of intestind flora in patients with liver cirrhosis and diarrhea[J].Inter Med Health Guid News,2011,17(6):678-679.(in Chinese)翁秋青.肝硬化及腹泻患者肠道菌群的比较研究[J].国际医药卫生导报,2011,17(6):678-679.
    [9]SON G,KREMER M,HINES IN.Contribution of gut bacteria to liver pathobiology[J].Gastroenterol Res Pract,2010,2010:pii453563.
    [10]ZHU Q,ZOU L,JAGAVELU K,et al.Intestinal decontamination inhibits TLR4 dependent fibronectin-mediated cross-talk between stellate cells and endothelial cells in liver fibrosis in mice[J].JHepatol,2012,56(4):893-899.
  • Cited by

    Periodical cited type(43)

    1. 刘洁,胡凯,刘钰,刘圆,王纳,尹蔚萍. 基于“肠道菌群”与肝脾的藏象关系探讨抽动障碍从肝脾论治的作用机制. 世界中西医结合杂志. 2025(02): 407-411 .
    2. 胡哲君,汤穆浛,张锐,金泓,严伦,何鸿志,曾凤兰,周志鹏. 基于“肝病实脾”理论探讨逍遥散对肝纤维化大鼠肝星状细胞铁死亡的影响. 陕西中医. 2024(02): 159-164+170 .
    3. 李水洪,韩秀珍,李岩,任娜,商洪涛. 基于肝脾相关理论辨治非酒精性脂肪性肝病. 中医学报. 2024(03): 534-541 .
    4. 杨必乾,何慧明,殷亭湄,付晓艳,高广淼,杨玲玲,李洁,邓毅. 中药调节肠道菌群缓解药物性肝损伤的研究进展. 上海中医药杂志. 2024(03): 92-96 .
    5. 王娜,吴伟,文彬,邓鑫. 基于“肠-肝轴”理论探讨中医药与肝纤维化的研究进展. 山西中医药大学学报. 2024(01): 109-112+118 .
    6. 杨必乾,何昱洁,何慧明,邓毅. 甘草及其复方调控肠道微生物改善药源性肝损伤的研究进展. 药学研究. 2024(04): 391-395 .
    7. 莫丹娥,邓鑫,丘佩容,张津浩,龚妙虹,庄烁琳. 粪菌移植治疗肝硬化及其并发症的研究进展. 云南中医中药杂志. 2024(07): 79-84 .
    8. 李坚宇,陈月桥,张燕燕,张雪,裴浩,孙叶. 基于“土壅木郁”理论探讨肝性脑病. 广西医学. 2024(07): 1106-1109 .
    9. 王姝婷,徐晓梅. 基于肠肝轴理论从肝脾论治肝纤维化研究进展. 中国中医药现代远程教育. 2024(20): 102-104 .
    10. 陈红艳,田琳. 基于肠道菌群-肠-脑轴从肝脾同调探讨偏头痛诊疗思路. 辽宁中医药大学学报. 2024(11): 134-137 .
    11. 郭耀东. 逍遥散加减联合富马酸丙酚替诺福韦片治疗肝郁脾虚型慢性乙型肝炎的临床观察. 中国民间疗法. 2023(02): 79-81+113 .
    12. 梁欣宇,林素琴,王一斌,徐静宜,刘雅萌,谢岑. 中药干预非酒精性脂肪性肝炎的机制研究进展. 南京中医药大学学报. 2023(04): 384-392 .
    13. 黄灿,沈垚村,刘深梵,祝捷,王志斌. 基于“肝-胆汁酸-肠道菌群轴”论非酒精性脂肪性肝病肝郁脾虚病机的生物学内涵. 北京中医药. 2023(05): 551-555 .
    14. 周剑波,傅伟强,吴雄健. 基于肠道菌群下肝性脑病的发病机制及治疗. 中国医药导报. 2023(19): 57-60+68 .
    15. 李萌,祁向争,周月. 逍遥散及其化裁方治疗慢性胃炎临床研究进展. 中国民族民间医药. 2023(17): 65-69 .
    16. 余思邈,李萍,李园,郑浩呈,王睿林,李宇航,丁霞. 从“见肝之病,知肝传脾,当先实脾”探讨肝硬化的防治. 北京中医药大学学报. 2022(01): 29-33 .
    17. 夏恩蕊,张素妍,田格格,陈文慧,张顺贞. 基于肠道屏障探讨中医药治疗非酒精性脂肪肝的研究进展. 云南中医中药杂志. 2022(03): 89-93 .
    18. 王宏强,李静,汪靖园,任江涛. 血清IL-6、hs-CRP、HSP70预测肝硬化并发肺部感染的价值. 临床医学研究与实践. 2022(19): 28-31 .
    19. 李卓娴,徐丽静,夏猛. 逍遥散类方治疗肝癌的研究进展. 环球中医药. 2022(08): 1491-1496 .
    20. 丁书凝,贾心如,阮善明,孙磊涛. 中医思辨体系中肠道菌群的共性分析和诊疗应用. 时珍国医国药. 2022(07): 1695-1697 .
    21. 刘礼剑,李建锋,陈广文,杨成宁,韦金秀,黎丽群,翁欣欣,谢胜. “肠-肝轴”与肝硬化相关性研究进展. 中国中西医结合消化杂志. 2021(03): 222-226 .
    22. 余丽华,李吉武. 论“脾主四时”与肠道菌群的相关性. 亚太传统医药. 2021(06): 210-213 .
    23. 温小雨,孙玉浩,徐丽静,夏猛. 加味逍遥散的应用及疗效研究进展. 大众科技. 2021(05): 45-47 .
    24. 杨佳慧,刘立萍,李然,管京京. 从气机升降探讨疏肝健脾方对乳腺癌患者肠道菌群-肿瘤微环境间串话的影响. 辽宁中医杂志. 2021(07): 108-110 .
    25. 黄祖鸿,石清兰,柏文婕,韦华柱,莫展进,邓霖霖. 毛德文教授运用“调肝理脾”法治疗慢性肝病经验总结. 陕西中医. 2021(08): 1112-1114+1119 .
    26. 牛亚蒙,刘江凯. 中医药对肝硬化患者肠道菌群的影响. 中西医结合肝病杂志. 2021(09): 861-864 .
    27. 孟雅楠,高艳,郝健亨,张玉伟,李振城,刘晋芳,刘杨,苗宇船. 基于网络药理学探讨逍遥散治疗非酒精性脂肪性肝炎的作用机制. 世界中西医结合杂志. 2021(09): 1626-1632 .
    28. 刘怀珍,胡晶晶,张莉. 柴芍二至散对甲亢性肝损害患者血IL-6、TNF-α的影响. 中国中西医结合杂志. 2020(02): 236-239 .
    29. 张欢,孙劲晖. 基于肠道微生态探索“调肝理脾”法治疗酒精性肝病的新思路. 中国医药导报. 2020(09): 123-126 .
    30. 陈越,陈兰玲. 基于肠道微生态探讨中医药防治慢性肝病的作用机制. 中医药临床杂志. 2020(04): 646-650 .
    31. 莫海霞,张华,蓝雪琴,梁婉桃,王梦莹. 产后抑郁与肠道菌群相关性中西医研究进展. 亚太传统医药. 2020(09): 193-196 .
    32. 徐梦君,曹守沛. 在动脉粥样硬化机制方面中药治疗的研究进展. 中医临床研究. 2020(28): 138-142 .
    33. 张辉凯,罗宏伟,孟祥林,李海雷,徐玉玲. 逍遥散对肝纤维化模型大鼠肝功能、肝纤维化指标的影响. 中医学报. 2019(02): 324-327 .
    34. 薛姣,王雄文,卢燊,严倩. 基于肝-肠轴探讨“实脾法”治疗肝癌的科学内涵. 中医杂志. 2019(07): 551-555 .
    35. 张丽丽,胡建华. 中医药对慢性肝病肠道微生态的影响研究现状. 北京中医药. 2019(03): 226-229 .
    36. 张岚,祝峻峰. 中医药治疗肝硬化肠道菌群失常的研究进展. 医学综述. 2019(21): 4286-4290 .
    37. 钱麟. 肠道菌群与中医药治疗疾病相关性研究进展. 浙江中西医结合杂志. 2018(07): 606-610 .
    38. 王倩,包永欣. 从肝病实脾论王乐亭“老实针”防治肝郁脾虚型溃疡性结肠炎. 辽宁中医药大学学报. 2018(10): 144-148 .
    39. 李燕珍,刘億,赵海梅,刘端勇,鹿秀云. 中医药调控肠道菌群的研究进展与思考. 中医研究. 2018(11): 72-77 .
    40. 柴智,杜珊,樊慧杰,陈文超,马艳苗,王永辉,李艳彦,周然. 逍遥散及其加减治疗肝病的临床应用及现代研究进展. 中华中医药杂志. 2017(08): 3631-3634 .
    41. 刘礼剑,杨成宁,沈飞霞,庞丽霞,梁楚佳,胡晓萍,黄瑞,谢胜,韦金秀. 基于“肠-肝轴”肠道菌群调节观察当归芍药散加味治疗肝硬化的临床疗效. 世界中医药. 2017(08): 1789-1792 .
    42. 石天闻,牟新,周迪夷. 中医药对肠道菌群影响的研究进展. 浙江中西医结合杂志. 2017(12): 1105-1109 .
    43. 曹婷,薛新娜,丁亚利. 中药治疗肠道菌群失调研究分析. 中国现代药物应用. 2017(19): 99-101 .

    Other cited types(17)

  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (2672) PDF downloads(470) Cited by(60)
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return